Work

Abstract CT209: DiscovHER PAN-206: Phase 2 tumor-agnostic study of zanidatamab in patients with previously treated human epidermal growth factor receptor 2-overexpressing solid tumors

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-ct209

Authors: Vivek Subbiah, Vicky Makker, Do-Youn Oh, Elizabeth Gardener, Elaina Gartner, Funda Meric-Bernstam

Institutions: Sarah Cannon, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, Seoul National University, Seoul National University Hospital, Oxford City Council, Oxford Spires Academy, Jazz Pharmaceuticals (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154753049

Cites:

Cited by:

Related to: